Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur Urol Focus ; 4(3): 405-411, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-28753809

RESUMO

BACKGROUND: The clinical diagnosis of urothelial carcinoma (UC) relies on invasive methods in patients with hematuria. Although more sensitive and noninvasive screening methods are required, a specific serum biomarker for UC is lacking. OBJECTIVE: To examine whether serum glycan-based biomarkers can be applied to UC detection. DESIGN, SETTING, AND PARTICIPANTS: Between April 1994 and June 2016, serum N-glycan concentrations were retrospectively measured in 212 patients with UC before treatment (UC group) and 212 pair-matched controls using glycoblotting and mass spectrometry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: N-glycan levels were compared between the groups using receiver operating characteristic curves to select candidate N-glycans. We created an N-glycan score based on the combination of candidate N-glycans. The specificity and sensitivity of the candidate N-glycan score were evaluated using receiver operating characteristic curves. RESULTS AND LIMITATIONS: The N-glycan score was calculated using six N-glycans (m/z 1566, m/z 1687, m/z 1769, m/z 1871, m/z 2011, and m/z 2337) that were significantly associated with UC. The median N-glycan score was significantly higher in the UC group than in the pair-matched control group (5.0 vs 1.0, p<0.001). The N-glycan score correctly classified UC patients with a sensitivity, specificity, and area under the curve of 93%, 81%, and 0.95, respectively. The limitations of our study included its retrospective nature and nonclinical setting. CONCLUSIONS: Serum N-glycan content has the potential to be a specific and sensitive novel serum biomarker that may improve the accuracy of the detection for UC and reduce unnecessary invasive screening. Validation of this test in a large-scale prospective study is needed. PATIENT SUMMARY: Combination of serum N-glycan (N-glycan score) is a novel serum marker for urothelial carcinoma that is expressed by 93% of patients and thus is far more sensitive than classic urine cytology. Validation in a large patient cohort is needed.


Assuntos
Carcinoma de Células de Transição/metabolismo , Polissacarídeos/sangue , Neoplasias Urológicas/metabolismo , Idoso , Biomarcadores Tumorais/sangue , Carcinoma de Células de Transição/patologia , Feminino , Hematúria/diagnóstico , Hematúria/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Gradação de Tumores/métodos , Estudos Retrospectivos , Sensibilidade e Especificidade , Urina/citologia , Neoplasias Urológicas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...